BioLife Solutions BLFS 深 沪
等待开盘 09-23 09:30:00 美东时间
38.07
+0.890
+2.39%
华盛通- 最 高38.28
- 今 开37.43
- 成交量 82.50万股
- 最 低 37.15
- 昨 收 37.18
- 总市值 18.63亿
- 52周最高 38.28
- 市盈率 静 --
- 换手率 1.69%
- 52周最低 17.86
- 委 比 -55.11%
- 总股本 4892.33万
- 历史最高 60.669
- 量 比 0.94
- 振 幅 3.04%
- 历史最低 0.02
- 每 手 1
- 风险率 4.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
09-12 01:06
BioLife Solutions Nears Completion of Repligen Acquisition
BioLife Solutions ( ($BLFS) ) just unveiled an announcement. On July 21, 2026, ...
09-10 06:19
Repligen clears antitrust hurdle in BioLife Solutions acquisition
Repligen ( ($RGEN) ) just unveiled an update. On July 21, 2026, Repligen entere...
09-09 06:10
BioLife Solutions Sets October Vote on Cash‑and‑Stock Merger With Repligen
New activity is brewing for BioLife Solutions ( ($BLFS) ). The company has subm...
09-05 05:57
Benchmark Downgrades BioLife Solutions to Hold
Benchmark analyst Robert Wasserman downgrades BioLife Solutions (NASDAQ:BLFS) from Buy to Hold.
08-10 21:40
BioLife Details Strategic Repligen Merger Communication to Staff
BioLife Solutions ( ($BLFS) ) has provided an update. On July 21, 2026, BioLife...
08-04 06:21
Repligen soars 16% after blockbuster earnings, FY25 guidance upgrade
Repligen (RGEN) shares rose as much as 16% during Tuesday’s trading following blockbuster second-quarter results and an upward revision to its full-year guidance. RGEN shares advanced 15.91% to $151.9...
07-29 02:49
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
美股大行评级 | 谷歌绩后分歧大！4家大行上调、10家下调目标价；特斯拉遭8家大行下调目标价；ServiceNow、德州仪器、西屋制动、AT&T、CSX等获多家大行上调目标价
今日重点评级关注：伯恩斯坦：维持ServiceNow"跑赢大市"评级，目标价从236美元升至248美元；HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从46美元升至52美元
07-24 11:37
